Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

An eQTL-based method identifies CTTN and ZMAT3 as pemetrexed susceptibility markers.

Human molecular genetics - 1 Apr 2012

Wen Yujia, Gamazon Eric R, Bleibel Wasim K, Wing Claudia, Mi Shuangli, McIlwee Bridget E, Delaney Shannon M, Duan Shiwei, Im Hae Kyung, Dolan M Eileen

Abstract excerpt

Pemetrexed, approved for the treatment of non-small cell lung cancer and malignant mesothelioma, has adverse effects including neutropenia, leucopenia, thrombocytopenia, anemia, fatigue and nausea. The results we report here represent the first genome-wide study aimed at identifying genetic predictors of pemetrexed response. We utilized expression quantitative trait loci (eQTLs) mapping combined with drug-induced...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Carrier Proteins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glutamates

Share to Guanine

Share to Linear Models

Share to Lymphocytes

Share to Pemetrexed

Share to RNA-Binding Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 22171072
DOI: 10.1093/hmg/ddr583
PMCID: PMC3298275

Genes

CTTN
ZMAT3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

An eQTL-based method identifies CTTN and ZMAT3 as pemetrexed susceptibility markers.PMID 22171072Read ↗

Transcriptomics based prediction of survival and response to therapy in malignant mesotheliomaSemantic proximity Read ↗

Pharmacogenetics of pemetrexed combination therapy in lung cancer: pathway analysis reveals novel toxicity associations.Semantic proximity Read ↗

Genomic and transcriptomic analyses identify a prognostic gene signature and predict response to therapy in pleural and peritoneal mesotheliomaSemantic proximity Read ↗

From Genes to Personalized Cancer Care: A Systematic Review of Toxicity-Associated Genetic Variants in Solid Tumor TreatmentsSemantic proximity Read ↗

Principled multi-omic analysis reveals gene regulatory mechanisms of phenotype variation.Semantic proximity Read ↗

Integration of genetic and functional genomics data to uncover chemotherapeutic induced cytotoxicity.Semantic proximity Read ↗

Predicting drug sensitivity of cancer cells based on DNA methylation levelsSemantic proximity Read ↗

Quantitative In Vivo Analyses Reveal a Complex Pharmacogenomic Landscape in Lung Adenocarcinoma.Semantic proximity Read ↗

Genomic Profile in a Non-Seminoma Testicular Germ-Cell Tumor Cohort Reveals a Potential Biomarker of Sensitivity to Platinum-Based TherapySemantic proximity Read ↗

Genomic profile in TGCT Mexican patients reveals a potential biomarker of sensitivity to platinum-based therapySemantic proximity Read ↗

Genetically regulated expression underlies cellular sensitivity to chemotherapy in diverse populationsSemantic proximity Read ↗

The pharmacoepigenomic landscape of cancer cell lines reveals the epigenetic component of drug sensitivitySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.